CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma

December 3-6, 2016; San Diego, California
Phase III study showed similar EFS and OS with both regimens and increased rate of adverse events with DA-EPOCH-R in DLBCL.
Format: Microsoft PowerPoint (.ppt)
File Size: 587 KB
Released: December 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

Downloadable slides on most current clinical data on frontline therapies for CLL.

Jeremy S. Abramson, MD, MMSc Released: December 3, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue